Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…Abstract Number: 1214 • 2019 ACR/ARP Annual Meeting
The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?
Background/Purpose: Multiple studies indicate hyperuricemia as an independent risk factor for hypertension. However, the association is found to be age-dependent and weakens as the patient…Abstract Number: 1215 • 2019 ACR/ARP Annual Meeting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Background/Purpose: Hyperuricemia, a common metabolic disorder, predisposes patients to develop gout due to the deposition of insoluble urate in joints. Safety concerns are frequently raised…Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…Abstract Number: 1219 • 2019 ACR/ARP Annual Meeting
Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
Background/Purpose: Hyperuricemia is associated with the development, progression and outcome of several diseases. The purpose of this study is to evaluate the serum uric acid…Abstract Number: 1220 • 2019 ACR/ARP Annual Meeting
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Background/Purpose: Prevention of gout flares is a central concern to patients with gout. There are many potential ways that gout flares could be reported in…Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…Abstract Number: 1222 • 2019 ACR/ARP Annual Meeting
Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration
Background/Purpose: Lack of a standardised allopurinol dose, with marked inter-individual variation in the dose required to achieve target urate contribute to failure to reach target…Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…Abstract Number: 1224 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Background/Purpose: AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric…Abstract Number: 1225 • 2019 ACR/ARP Annual Meeting
Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound
Background/Purpose: To evaluate limits of detection of ultrasound to detect monosodium urate crystals suspended in synovial fluid.Methods: Serial dilutions were made mixing liquid tophus aspirated…Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…
ACR Meeting Abstracts